Genmab Posts Q1 Net Profit Surge; Revenue Jumps
Genmab (GMAB.CO) said Thursday net profit for the first quarter surged as revenue jumped year over year. Net profit for the three months ended March 31 was 1.33 billion Danish kroner, compared with 21
MT Newswires22:48 ET
Top Gap Ups and Downs on Thursday: LIN, ING, JD and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo News19:39 ET
Genmab Reports Q1 Results
Seeking AlphaMay 2 11:05 ET
Express News | Genmab Q1 2024 Revenue $604.25M
BenzingaMay 2 11:05 ET
Press Release: Genmab Announces Financial Results for the First Quarter of 2024
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights -- The U.S. Food and Drug
Dow JonesMay 2 11:01 ET
Top Gap Ups and Downs on Wednesday: JNJ, AMD, PFE and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsMay 1 19:27 ET
Genmab Q1 2024 Earnings Preview
Seeking AlphaMay 1 14:28 ET
Top Gap Ups and Downs on Tuesday: LLY, HSBC, TT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 30 19:36 ET
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer
Pfizer (PFE) and Genmab (GMAB) said Monday that the US Food and Drug Administration approved a supplemental biologics license application for Tivak to treat patients with recurrent or metastatic cervi
MT NewswiresApr 30 11:16 ET
Decoding 9 Analyst Evaluations For Genmab
Throughout the last three months, 9 analysts have evaluated Genmab (NASDAQ:GMAB), offering a diverse set of opinions from bullish to bearish.The table below offers a condensed view of their recent rat
BenzingaApr 30 08:00 ET
Genmab's TIVDAK Wins Full FDA Approval
TipRanksApr 30 07:28 ET
Express News | HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
BenzingaApr 30 06:22 ET
Genmab Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 76.93% HC Wainwright & Co. → $50 Reiterates Buy → Buy 04/04/2024 76.93% HC Wainwright & Co. → $
BenzingaApr 30 06:20 ET
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug
By Ben Glickman Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer. The companies' drug Tivdak had previou
WSJApr 29 18:53 ET
TIVDAK (Tisotumab Vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Genmab A/S (NASDAQ:GMAB) and Pfizer Inc. (NYSE:PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first antibody-drug conjugate (ADC) with demonstrated overall survival data to be granted full FDA approval in this patient population.
Globe NewswireApr 29 18:40 ET
A watershed in ADC track investment has emerged, and “false competition+hematopoietic research and development” has become a new weather vane?
In particular, at a time when market expectations of the Federal Reserve's interest rate cut have declined sharply, and the global biomedical financing environment is far from improving, investors are more willing to look at companies with greater certainty.
Zhitong FinanceApr 26 04:18 ET
Top Gap Ups and Downs on Thursday: META, AZN, CAT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 25 20:13 ET
Top Gap Ups and Downs on Wednesday: TSLA, TXN, BSX and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
moomoo NewsApr 24 19:42 ET
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)
TipRanksApr 16 20:21 ET
J&J Sets Guidance Below Consensus as MedTech Underperforms
Seeking AlphaApr 16 07:20 ET
No Data
No Data